Skip to content

house · Committee report

H. Rept. 118-757

340B TRANSPARENCY ACT

2024-11-20

Committees

Associated legislation

Text

Minority Views

[To accompany H.R. 3290] The Committee on Energy and Commerce, to whom was referred the bill (H.R. 3290) to amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program, having considered the same, reports favorably thereon with an amendment and recommends that the bill as amended do pass. CONTENTS Page Purpose and Summary.............................................. 4 Background and Need for Legislation.............................. 4 Committee Action................................................. 4 Committee Votes.................................................. 5 Oversight Findings and Recommendations........................... 7 New Budget Authority, Entitlement Authority, and Tax Expenditures 7 Congressional Budget Office Estimate............................. 7 Federal Mandates Statement....................................... 7 Statement of General Performance Goals and Objectives............ 7 Duplication of Federal Programs.................................. 7 Related Committee and Subcommittee Hearings...................... 7 Committee Cost Estimate.......................................... 7 Earmarks, Limited Tax Benefits, and Limited Tariff Benefits...... 8 Advisory Committee Statement..................................... 8 Applicability to Legislative Branch.............................. 8 Section-by-Section Analysis of the Legislation................... 8 Changes in Existing Law Made by the Bill, as Reported............ 8 Minority Views................................................... 21 The amendment is as follows: Strike all after the enacting clause and insert the following: SECTION 1. SHORT TITLE. This Act may be cited as the ``340B Transparency Act''. SEC. 2. ENSURING TRANSPARENCY AND OVERSIGHT OF THE 340B DRUG DISCOUNT PROGRAM. (a) In General.--Section 340B(a)(5) of the Public Health Service Act (42 U.S.C. 256b(a)(5)) is amended-- (1) in subparagraph (C)-- (A) by striking ``A covered entity shall permit'' and inserting: ``(i) Duplicate discounts and drug resale.--A covered entity shall permit''; and (B) by adding at the end the following new clauses: ``(ii) Use of savings.--A covered entity shall permit the Secretary to audit, at the Secretary's expense, the records of the entity to determine-- ``(I) how savings (as defined in subparagraph (E)(iv)) from covered outpatient drugs subject to an agreement under this section furnished by such entity are used by such entity; and ``(II) such entity's compliance with subparagraph (E). ``(iii) Records retention.--Covered entities shall retain such records and provide such records and reports as determined necessary by the Secretary for carrying out this subparagraph.''; and (2) by adding at the end the following new subparagraph: ``(E) Reporting.-- ``(i) In general.--During the first year beginning on or after the date that is 14 months after the date of enactment of this subparagraph and during each subsequent year, each covered entity described in subparagraph (L) of paragraph (4) (and any other covered entity specified by the Secretary) shall report to the Secretary (at a time and in a form and manner specified by the Secretary) the following information with respect to the preceding year: ``(I) With respect to such covered entity and each off-campus outpatient department, as applicable, of such entity-- ``(aa) the total number of individuals who were dispensed or administered covered outpatient drugs during such preceding year that were subject to an agreement under this section; and ``(bb) the number of such individuals described in a category specified in clause (iv), broken down by each such category. ``(II) With respect to such covered entity and each off-campus outpatient department, as applicable, of such entity-- ``(aa) the percentage of the total number of individuals furnished items and services during such preceding year who were dispensed or administered covered outpatient drugs during such preceding year that were subject to an agreement under this section; and ``(bb) for each category specified in clause (iii), the percentage of the total number of individuals described in such category furnished items and services during such preceding year who were dispensed or administered covered outpatient drugs during such preceding year that were subject to an agreement under this section. ``(III) With respect to such covered entity and each off-campus outpatient department, as applicable, of such entity, the total costs incurred during the year at each such site and the cost incurred at each such site for charity care (as defined in line 23 of worksheet S-10 to the Medicare cost report, or in any successor form). ``(IV) With respect to such covered entity and each off-campus outpatient department, as applicable, of such entity, the costs incurred during the year of furnishing items and services at each such department to patients of such entity who were entitled to benefits under part A of title XVIII of the Social Security Act or enrolled under part B of such title, enrolled in a State plan under title XIX of such Act (or a waiver of such plan), or who were uninsured for services, minus the sum of-- ``(aa) payments under title XVIII of such Act for such items and services (including any cost sharing for such items and services); ``(bb) payments under title XIX of such Act for such items and services (including any cost sharing for such items and services); and ``(cc) payments by uninsured patients for such items and services. ``(V) With respect to such covered entity and each off-campus outpatient department, as applicable, of such entity, savings (as defined in clause (iv)) from covered outpatient drugs subject to an agreement under this section furnished by such entity or department. ``(ii) Publication.--The Secretary shall publish data reported under clause (i) with respect to a year annually on the public website of the Department of Health and Human Services in an electronic and searchable format, which may include the 340B Office of Pharmacy Affairs Information System (or a successor to such system), in a manner that shows each category of data reported in the aggregate and identified by the specific covered entity submitting such data. The Secretary shall include in such publication the disproportionate patient percentage (as defined in section 1886(d)(5)(F)(vi) of the Social Security Act) of each such covered entity (if applicable) for each cost reporting period occurring during such year. ``(iii) Categories specified.--For purposes of clause (i), the categories specified in this clause are the following: ``(I) Individuals covered under a group health plan or group or individual health insurance coverage (as such terms are defined in section 2791). ``(II) Individuals entitled to benefits under part A or enrolled under part B of title XVIII of the Social Security Act. ``(III) Individuals enrolled under a State plan under title XIX of such Act (or a waiver of such plan). ``(IV) Individuals enrolled under a State child health plan under title XXI of such Act (or a waiver of such plan). ``(V) Individuals not described in any preceding subclause and not covered under any Federal health care program (as defined in section 1128B of such Act but including the program established under chapter 89 of title 5, United States Code). ``(iv) Definitions.--For purposes of this subparagraph: ``(I) Off-campus outpatient department.--The term `off-campus outpatient department' means a department of a provider (as defined in section 413.65 of title 42, Code of Federal Regulations, or any successor regulation) that is not located-- ``(aa) on the campus (as defined in such section) of such provider; or ``(bb) within the distance (described in such definition of campus) from a remote location of a hospital facility (as defined in such section). ``(II) Savings.--The term `savings' means, with respect to a covered outpatient drug purchased by a covered entity, the difference between-- ``(aa) the price for such drug that such entity would have otherwise paid for such drug obtained through a group purchasing organization or other group purchasing arrangement had the requirement described in paragraph (4)(L)(iii) not applied (or, in the case such entity would not have obtained covered outpatient drugs through such an organization or arrangement had such requirement not applied or information to determine such price that such entity would have so otherwise paid is not available, the wholesale acquisition cost (as defined in section 1847A(c)(6)(B) of the Social Security Act) for such drug); and ``(bb) the ceiling price for such drug.''. (b) Enforcement.--Section 340B(d)(2)(B) of the Public Health Service Act (42 U.S.C. 256b(d)(2)(B)) is amended by adding at the end the following new clause: ``(vi) The imposition of civil monetary penalties in amounts determined appropriate by the Secretary in the case that the Secretary determines that a covered entity is not in compliance with subsection (a)(5)(E) .''. (c) Rulemaking.--Not later than 180 days after the date of the enactment of this Act, the Secretary of Health and Human Services shall issue an interim final rule to carry out section 340B(a)(5)(E) of the Public Health Service Act, as added by subsection (a)(2).

Purpose and Summary

This bill requires disproportionate share hospitals (DSH) hospitals participating in the Public Health Service Act's ``340B'' Drug Discount Program to report on net savings from the Program and other relevant metrics.

Background and Need for Legislation

The 340B Drug Discount Program provides for opportunities for covered entities in the Program to purchase drugs at discounts and to receive reimbursements for the drugs at standard prices, thus allowing for the covered entity to receive reimbursements in excess of what the covered entity would have otherwise received without participation in the Program. In providing additional revenue to covered entities, the Program allows for covered entities to provide additional resources to patients and their communities at a loss. In recent years, the 340B Program has come under fire for the opacity of its size and scope and the potential for its lucrative savings to encourage consolidation in the health care sector as hospitals seek to expand their 340B footprint. While some estimates claim that the Program is worth about $30-$60 billion per year, there is little data to verify the accuracy of this claim or the allegations that the Program furthers consolidation. Furthermore, there is no standardized reporting to understand the usages of the Program and what value the Program brings to respective covered entities. As such, the bill would require standardized of the size and scope of the Program for DSH hospitals that participate in the Program, and it would allow for the Secretary to increase reporting requirements for additional covered entities beyond just DSH hospitals. Among the reporting requirements in the bill are requirements to disclose a covered entity's net savings from the Program, a covered entity's patient mix, a covered entity's charity care, and a covered entity's payer shortfall (including reporting for all relevant categories at respective, outpatient facilities for a covered entity). The bill would also establish civil monetary penalties for noncompliance.

Committee Action

On April 26, 2023, the Subcommittee on Health held a hearing on H.R. 3290. The title of the hearing was ``Lowering Unaffordable Costs: Legislative Solutions to Increase Transparency and Competition in Health Care.'' The Subcommittee received testimony from: Ashley Thompson, Senior Vice President, Public Policy Analysis and Development, American Hospital Association. On May 17, 2023, the Subcommittee on Health met in open markup session and forwarded H.R. 3290 as amended, to the full Committee by a recorded vote of 16 yeas and 12 nays. On May 24, 2023, the full Committee on Energy and Commerce met in open markup session and ordered H.R. 3290, as amended, favorably reported to the House by a recorded vote of 29 yeas and 22 nays.

Committee Votes

The following reflects the record votes taken during the Committee consideration: [GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] Oversight Findings and Recommendations Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of rule XIII, the Committee held a hearing and made findings that are reflected in this report. New Budget Authority, Entitlement Authority, and Tax Expenditures Pursuant to clause 3(c)(2) of rule XIII, the Committee finds that H.R. 3290 would result in no new or increased budget authority, entitlement authority, or tax expenditures or revenues.

Congressional Budget Office Estimate

Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not available. Federal Mandates Statement The Committee adopts as its own the estimate of Federal mandates prepared by the Director of the Congressional Budget Office pursuant to section 423 of the Unfunded Mandates Reform Act. Statement of General Performance Goals and Objectives Pursuant to clause 3(c)(4) of rule XIII, the general performance goal or objective of this legislation is to ensure transparency and oversight of the 340B Drug Discount Program. Duplication of Federal Programs Pursuant to clause 3(c)(5) of rule XIII, no provision of H.R. 3290 is known to be duplicative of another Federal program, including any program that was included in a report to Congress pursuant to section 21 of Public Law 111-139 or the most recent Catalog of Federal Domestic Assistance. Related Committee and Subcommittee Hearings Pursuant to clause 3(c)(6) of rule XIII, the following hearing was used to develop or consider H.R. 3290: On April 26, 2023, the Subcommittee on Health held a hearing on H.R. 3290. The title of the hearing was ``Lowering Unaffordable Costs: Legislative Solutions to Increase Transparency and Competition in Health Care.'' The Subcommittee received testimony from: Ashley Thompson, Senior Vice President, Public Policy Analysis and Development, American Hospital Association. Committee Cost Estimate Pursuant to clause 3(d)(1) of rule XIII, the Committee adopts as its own the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974. At the time this report was filed, the estimate was not available. Earmarks, Limited Tax Benefits, and Limited Tariff Benefits Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the Committee finds that H.R. 3290 contains no earmarks, limited tax benefits, or limited tariff benefits. Advisory Committee Statement No advisory committees within the meaning of section 5(b) of the Federal Advisory Committee Act were created by this legislation. Applicability to Legislative Branch The Committee finds that the legislation does not relate to the terms and conditions of employment or access to public services or accommodations within the meaning of section 102(b)(3) of the Congressional Accountability Act. Section-by-Section Analysis of the Legislation Section 1. Short title Section 1 provides a short title of the ``340B Transparency Act.'' Section 2. Ensuring transparency and oversight of the 340B drug discount program Section 2 would require DSH hospitals participating in the 340B Program, as well as the covered entity's respective outpatient facilities, to report certain information. The information that must be reported includes: the net savings from the 340B Program for the covered entity; the patient mix for the covered entity; the charity care for the covered entity; and the payer shortfall for the covered entity. In addition, section 2 would permit the Secretary to expand reporting requirements to additional covered entities beyond just DSH hospitals. It would also establish civil monetary penalties for covered entities not in compliance with the law. Changes in Existing Law Made by the Bill, as Reported In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as follows (existing law proposed to be omitted is enclosed in black brackets, new matter is printed in italics, and existing law in which no change is proposed is shown in roman): PUBLIC HEALTH SERVICE ACT * * * * * * * TITLE III--GENERAL POWERS AND DUTIES OF PUBLIC HEALTH SERVICE * * * * * * * Part D--Primary Health Care * * * * * * * Subpart VII--Drug Pricing Agreements limitation on prices of drugs purchased by covered entities Sec. 340B. (a) Requirements for Agreement With Secretary.-- (1) In general.--The Secretary shall enter into an agreement with each manufacturer of covered outpatient drugs under which the amount required to be paid (taking into account any rebate or discount, as provided by the Secretary) to the manufacturer for covered outpatient drugs (other than drugs described in paragraph (3)) purchased by a covered entity on or after the first day of the first month that begins after the date of the enactment of this section, does not exceed an amount equal to the average manufacturer price for the drug under title XIX of the Social Security Act in the preceding calendar quarter, reduced by the rebate percentage described in paragraph (2). Each such agreement shall require that the manufacturer furnish the Secretary with reports, on a quarterly basis, of the price for each covered outpatient drug subject to the agreement that, according to the manufacturer, represents the maximum price that covered entities may permissibly be required to pay for the drug (referred to in this section as the ``ceiling price''), and shall require that the manufacturer offer each covered entity covered outpatient drugs for purchase at or below the applicable ceiling price if such drug is made available to any other purchaser at any price. (2) Rebate percentage defined.-- (A) In general.--For a covered outpatient drug purchased in a calendar quarter, the ``rebate percentage'' is the amount (expressed as a percentage) equal to-- (i) the average total rebate required under section 1927(c) of the Social Security Act with respect to the drug (for a unit of the dosage form and strength involved) during the preceding calendar quarter; divided by (ii) the average manufacturer price for such a unit of the drug during such quarter. (B) Over the counter drugs.-- (i) In general.--For purposes of subparagraph (A), in the case of over the counter drugs, the ``rebate percentage'' shall be determined as if the rebate required under section 1927(c) of the Social Security Act is based on the applicable percentage provided under section 1927(c)(3) of such Act. (ii) Definition.--The term ``over the counter drug'' means a drug that may be sold without a prescription and which is prescribed by a physician (or other persons authorized to prescribe such drug under State law). (3) Drugs provided under state medicaid plans.--Drugs described in this paragraph are drugs purchased by the entity for which payment is made by the State under the State plan for medical assistance under title XIX of the Social Security Act. (4) Covered entity defined.--In this section, the term ``covered entity'' means an entity that meets the requirements described in paragraph (5) and is one of the following: (A) A Federally-qualified health center (as defined in section 1905(l)(2)(B) of the Social Security Act). (B) An entity receiving a grant under section 340A. (C) A family planning project receiving a grant or contract under section 1001. (D) An entity receiving a grant under subpart II of part C of title XXVI (relating to categorical grants for outpatient early intervention services for HIV disease). (E) A State-operated AIDS drug purchasing assistance program receiving financial assistance under title XXVI. (F) A black lung clinic receiving funds under section 427(a) of the Black Lung Benefits Act. (G) A comprehensive hemophilia diagnostic treatment center receiving a grant under section 501(a)(2) of the Social Security Act. (H) A Native Hawaiian Health Center receiving funds under the Native Hawaiian Health Care Act of 1988. (I) An urban Indian organization receiving funds under title V of the Indian Health Care Improvement Act. (J) Any entity receiving assistance under title XXVI (other than a State or unit of local government or an entity described in subparagraph (D)), but only if the entity is certified by the Secretary pursuant to paragraph (7). (K) An entity receiving funds under section 318 (relating to treatment of sexually transmitted diseases) or section 317(j)(2) (relating to treatment of tuberculosis) through a State or unit of local government, but only if the entity is certified by the Secretary pursuant to paragraph (7). (L) A subsection (d) hospital (as defined in section 1886(d)(1)(B) of the Social Security Act) that-- (i) is owned or operated by a unit of State or local government, is a public or private non-profit corporation which is formally granted governmental powers by a unit of State or local government, or is a private non-profit hospital which has a contract with a State or local government to provide health care services to low income individuals who are not entitled to benefits under title XVIII of the Social Security Act or eligible for assistance under the State plan under this title; (ii) for the most recent cost reporting period that ended before the calendar quarter involved, had a disproportionate share adjustment percentage (as determined under section 1886(d)(5)(F) of the Social Security Act) greater than 11.75 percent or was described in section 1886(d)(5)(F)(i)(II) of such Act; and (iii) does not obtain covered outpatient drugs through a group purchasing organization or other group purchasing arrangement. (M) A children's hospital excluded from the Medicare prospective payment system pursuant to section 1886(d)(1)(B)(iii) of the Social Security Act, or a free-standing cancer hospital excluded from the Medicare prospective payment system pursuant to section 1886(d)(1)(B)(v) of the Social Security Act, that would meet the requirements of subparagraph (L), including the disproportionate share adjustment percentage requirement under clause (ii) of such subparagraph, if the hospital were a subsection (d) hospital as defined by section 1886(d)(1)(B) of the Social Security Act. (N) An entity that is a critical access hospital (as determined under section 1820(c)(2) of the Social Security Act), and that meets the requirements of subparagraph (L)(i). (O) An entity that is a rural referral center, as defined by section 1886(d)(5)(C)(i) of the Social Security Act, or a sole community hospital, as defined by section 1886(d)(5)(C)(iii) of such Act, and that both meets the requirements of subparagraph (L)(i) and has a disproportionate share adjustment percentage equal to or greater than 8 percent. (5) Requirements for covered entities.-- (A) Prohibiting duplicate discounts or rebates.-- (i) In general.--A covered entity shall not request payment under title XIX of the Social Security Act for medical assistance described in section 1905(a)(12) of such Act with respect to a drug that is subject to an agreement under this section if the drug is subject to the payment of a rebate to the State under section 1927 of such Act. (ii) Establishment of mechanism.--The Secretary shall establish a mechanism to ensure that covered entities comply with clause (i). If the Secretary does not establish a mechanism within 12 months under the previous sentence, the requirements of section 1927(a)(5)(C) of the Social Security Act shall apply. (B) Prohibiting resale of drugs.--With respect to any covered outpatient drug that is subject to an agreement under this subsection, a covered entity shall not resell or otherwise transfer the drug to a person who is not a patient of the entity. (C) Auditing.--[A covered entity shall permit] (i) Duplicate discounts and drug resale._A covered entity shall permit the Secretary and the manufacturer of a covered outpatient drug that is subject to an agreement under this subsection with the entity (acting in accordance with procedures established by the Secretary relating to the number, duration, and scope of audits) to audit at the Secretary's or the manufacturer's expense the records of the entity that directly pertain to the entity's compliance with the requirements described in subparagraphs (A) or (B) with respect to drugs of the manufacturer. (ii) Use of savings.--A covered entity shall permit the Secretary to audit, at the Secretary's expense, the records of the entity to determine-- (I) how savings (as defined in subparagraph (E)(iv)) from covered outpatient drugs subject to an agreement under this section furnished by such entity are used by such entity; and (II) such entity's compliance with subparagraph (E). (iii) Records retention.--Covered entities shall retain such records and provide such records and reports as determined necessary by the Secretary for carrying out this subparagraph. (D) Additional sanction for noncompliance.-- If the Secretary finds, after audit as described in subparagraph (C) and after notice and hearing, that a covered entity is in violation of a requirement described in subparagraphs (A) or (B), the covered entity shall be liable to the manufacturer of the covered outpatient drug that is the subject of the violation in an amount equal to the reduction in the price of the drug (as described in subparagraph (A)) provided under the agreement between the entity and the manufacturer under this paragraph. (E) Reporting.-- (i) In general.--During the first year beginning on or after the date that is 14 months after the date of enactment of this subparagraph and during each subsequent year, each covered entity described in subparagraph (L) of paragraph (4) (and any other covered entity specified by the Secretary) shall report to the Secretary (at a time and in a form and manner specified by the Secretary) the following information with respect to the preceding year: (I) With respect to such covered entity and each off- campus outpatient department, as applicable, of such entity-- (aa) the total number of individuals who were dispensed or administered covered outpatient drugs during such preceding year that were subject to an agreement under this section; and

Minority Views

H.R. 3290 will provide information that will obscure how the 340B program works and misconstrue the value of the program to patients rather than provide transparency into the program. The legislation would require hospitals that participate in the 340B program to report on the savings they receive from the program and compare that with their costs for charity care, or costs incurred for caring for Medicaid and Medicare patients and the uninsured. However, reports would not include opportunities for covered entities to explain other ways they use savings to expand care. Covered entities have voluntarily shared that they use 340B savings to provide low-cost drugs to patients, improve medication management, and help patients with complex care needs get connected with specialists and social services.\1\ --------------------------------------------------------------------------- \1\340B Health, 2021 340B Health Annual Survey: 340B Continues to Support Essential Programs and Services in the Face of Significant Financial Stress on Hospitals (https://www.340bhealth.org/files/ 340B_Health_Survey_Report_2021_FINAL.pdf). --------------------------------------------------------------------------- These activities all provide value and benefit for patients, but would not necessarily be captured in the reporting metrics listed in the bill. By limiting the view of the program to just a narrow band of metrics, the reports produced by this legislation could imply that the program is not providing benefits. The bill also fails to include transparency or program integrity measures regarding participating pharmaceutical manufacturers, at a time when many large drug companies are openly violating the law by failing to deliver drugs to covered entities' contract pharmacies.\2\ Pharmaceutical manufacturers' failure to comply with the 340B statute is costing millions of dollars to hospitals and other covered entities, and H.R. 3290 does nothing to address this issue. --------------------------------------------------------------------------- \2\Fierce Pharma, AHA: Drugmaker 340B restrictions are harming safety net hospitals financially (https://www.fiercehealthcare.com/ providers/aha-drug-maker-340b-restrictions-are-harming-safety-net- hospitals-financially) (Nov. 15, 2022). --------------------------------------------------------------------------- The Health Resources and Services Administration (HRSA), the agency charged with overseeing the 340B program, already has several requirements in place for covered entities, including annual recertification, and audits of covered entities for compliance with the law. This bill would expand HRSA's responsibilities to further audit the use of covered entities' savings. Unfortunately, the legislation includes no additional resources for the agency to conduct these audits. With only 23 staff overseeing the 340B program, additional program integrity measures will require not only more responsibilities, but more authority and resources. H.R. 3290, as amended and passed by the Full Committee, brings little transparency to the 340B program, and may make the benefits of the program to patients and communities more difficult to understand. It provides no additional resources for audits or authorities to help bring program integrity to the 340B program. Frank Pallone, Jr., Ranking Member. [all]

Source: https://api.congress.gov/v3/committee-report/118/hrpt/757